乳腺癌骨转移患者立体定向体部放疗后循环T细胞的动态反应
研究分析30例乳腺癌骨转移患者接受立体定向体部放疗(SBRT)后外周血T细胞变化,发现SBRT后1周循环PD-1+ CD8+ T细胞和调节性T(TREG)细胞均被激活,TREG细胞激活与更差的无进展生存相关,作者认为结果可能支持联合TREG细胞调节策略。
要点
- SBRT后1周循环PD-1+ CD8+ T细胞和TREG细胞均被激活。
- TREG细胞激活在PD-1+ CD8+ T细胞激活更强的患者中更明显。
- SBRT后1周TREG细胞激活与更差的无进展生存相关。
核心结论
- SBRT诱导了潜在肿瘤特异性CD8+ T细胞和TREG细胞的激活,两者紧密相关。
- 这些结果可能支持使用TREG细胞调节策略联合SBRT以改善抗肿瘤免疫反应。
研究设计与样本
- 研究纳入30例因骨转移接受SBRT的乳腺癌患者,采用多色流式细胞术分析外周血样本。
- 检测PD-1+ CD8+ T细胞和调节性T(TREG)细胞表型,并用基于微珠的免疫分析法分析血浆蛋白水平。
主要发现
- 循环PD-1+ CD8+ T细胞(富集肿瘤特异性克隆型)在SBRT后1周被激活。
- 循环TREG细胞在SBRT后也被激活,效应性Foxp3hiCD45RA- TREG细胞中亦可见此模式。
- 未观察到T细胞反应随分次剂量和分次数不同而有差异。
- TREG细胞激活在PD-1+ CD8+ T细胞激活更强的患者中更明显。
- SBRT后1周血浆TGF-β1、可溶性CTLA-4和可溶性4-1BB水平变化与PD-1+ CD8+ T细胞反应相关。
关键数值与推荐
- SBRT后1周TREG细胞激活与更差的无进展生存相关。
- 包括分子分型在内的临床因素与T细胞反应无关。
临床怎么用
- 作者认为结果可能支持使用TREG细胞调节策略联合SBRT以改善抗肿瘤免疫反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies have shown that radiation therapy modulates antitumor immune responses. However, circulating T-cell responses after radiation therapy in patients with cancer have been poorly characterized. This study aims to explore the changes in circulating T cells after stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Peripheral blood samples of 30 patients with breast cancer who underwent SBRT for bone metastasis were analyzed using multicolor flow cytometry. Phenotypes of PD-1+ CD8+ T cells and regulatory T (TREG) cells were examined. Additionally, plasma protein levels were analyzed using a bead-based immunoassay. RESULTS: Circulating PD-1+ CD8+ T cells, which are enriched for tumor-specific clonotypes, were activated at 1 week after SBRT. However, circulating TREG cells were also activated after SBRT; this pattern was also evident among effector Foxp3hiCD45RA- TREG cells. We observed no difference in T-cell responses according to the fraction size and number. Notably, activation of TREG cells was more prominent in patients who experienced greater activation of PD-1+ CD8+ T cells. Plasma level changes in TGF-β1, soluble CTLA-4, and soluble 4-1BB at 1 week after SBRT were associated with PD-1+ CD8+ T-cell responses. Activation of TREG cells at 1 week after SBRT was associated with worse progression-free survival. Clinical factors including molecular subtype were not associated with the T-cell responses. CONCLUSIONS: SBRT induced activation of both potentially tumor-specific CD8+ T cells and TREG cells, which were tightly associated with each other. These results may support the use of TREG cell-modulating strategies with SBRT to improve the antitumor immune response.
引用
- Jeon SH, Jang BS, Kim DY, et al. Dynamic Responses of Circulating T Cells After Stereotactic Body Radiation Therapy for Bone Metastasis in Patients With Breast Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37802227. doi:10.1016/j.ijrobp.2023.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。